Operational update on strategic investments

21 November 2019

Braveheart Investment Group plc

("Braveheart" or the "Company")

Operational update on strategic investments

Braveheart Investment Group plc (AIM: BRH), the fund management and strategic investor Group, is pleased to provide shareholders with an operational update on its strategic investments. The Board will seek to issue further operational updates in due course.

Paraytec Limited (holding 100%)

The Innovate UK funded R&D project ("NEXUS") with partners Malvern Panalytical, the University of Central Lancashire, GSK, Medimmune and Fujifilm Diosynth is building towards the second round of end user trials of the prototype instrument for measuring protein aggregation in biopharmaceuticals. Aggregates are an impurity that must be controlled and must stay within product specifications, so measurement is essential to ensure they meet the requirements of regulatory agencies. The trials are scheduled for January/February 2020.

Chief Scientific Officer Prof David Goodall is presenting a poster relating to developments completed under the NEXUS project at PEGS Europe (the largest protein & antibody engineering summit in Europe) in Lisbon later this month.

Pharm 2 Farm Limited (holding 33.33%)

Pharm 2 Farm Limited ("Pharm2Farm") is working with partners to bid into the £90 million Innovate UK grant funding available to help agritech businesses, researchers and industry to transform food production.

The aim of this project is to find new ways of producing foods that are high in nutritional value and can deliver multiple harvests per season. Pharm2Farm's products are designed to help deliver this by improving the bioavailability of micronutrients, which are essential for healthy growth in; plants, animals, insects and aquaculture.

The company has recently increased its headcount with the appointment of a new sales manager, whose role is to lead, direct and distribute sales across the Agriculture, Horticulture, Hydroponics and Amenity markets in the UK and globally.

Kirkstall Limited (holding 64.67%)

The first annual review is about to take place in Brussels for the €4.7 million Horizon 2020 project which Kirkstall Limited ("Kirkstall") is involved in with a number of prestigious European Universities. The research project is in the field of Cybergenetic Tissue Engineering, developing techniques to grow human organs by using light to modify the growth of cells. Kirkstall is providing specialist Quasi-Vivo products in which the cell cultures will be grown.

Kirkstall's annual conference, Advances in Cell and Tissue Culture ("ACTC") 2020, is confirmed for 2-3 June 2020 at Cardiff University (www.theACTC.com). Promotional activity and the signing of exhibitors and delegates is underway.

Gyrometric Systems Limited (holding 19.95%)

Continued development of Gyrometric Systems Limited's ("Gyrometric Systems") monitoring and measurement systems has enabled the range of all systems to be extended downwards to as low as 0.25 revolutions per minute. This is of particular use in monitoring wind turbines.

The effectiveness of the combination of Gyrometric Measurement Technology on rotating shafts, and the Internet of Things is gaining recognition in wider industries, from cement manufacture, to power generation and to transport. These industries are all dependent on the reliability of rotating shafts.

Gyrometric Systems ship drive monitoring systems will be exhibited at SMM Hamburg on 8-11 September 2020. SMM Hamburg is the world's largest exhibition for ship technology.

Phasefocus Holdings Limited (holding 21.20%)

On 5 November 2019, Phasefocus Holdings Limited ("Phasefocus") was granted a new US patent for a fundamental improvement in its underlying ptychography imaging technology. The new patent brings the total number of granted patents owned by Phasefocus to 109, with coverage in all major territories around the world. The method protected by the new patent has the potential to speed up Phasefocus's systems by a factor of 10 times and could pave the way for new instruments capable of monitoring dynamic intracellular processes.

Sentinel Medical Limited (holding 38.40%)

Initial trials testing 'live' samples in the prototype instrument to detect bladder cancer from urine have now been completed. Whilst important progress had been made, the conclusion reached from the initial trials was that test protocols need to be revised. This work is currently being undertaken at Sheffield University using urine samples from healthy volunteers. Once the revised protocol is defined then patient tests using 'live' samples will be re-started.

For further information: